We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NXPL:NASDAQNextPlat Corp Analysis

Data as of 2026-04-21 - not real-time

$5.69

Latest Price

8/10Risk

Risk Level: High

Executive Summary

NextPlat Corp (NXPL) posted FY2025 revenue of $54 million, an 18% YoY decline, and continues to run deep losses with a gross margin of only 20% and operating margin of –27%, highlighting a distressed operating profile. The company announced a 1‑for‑10 reverse stock split in April 2026, a move that underscores its low share price and attempts to boost market perception. Technical signals are mixed: the 20‑day SMA ($5.07) is marginally above the 50‑day SMA ($5.06) while both sit well below the 200‑day SMA ($6.68), producing a **neutral trend**; the RSI at 57 suggests neither overbought nor oversold conditions; and the MACD histogram is positive (0.12) with a bullish signal line, indicating modest short‑term momentum. Volume has been decreasing, and the stock trades at a price‑to‑book of 0.88 and a price‑to‑sales of 0.28, which appear attractive on a pure multiple basis but are offset by negative earnings and a high debt‑to‑equity ratio of 9.0. Volatility is extreme at 135% over the past 30 days and beta of 1.41 signals heightened market sensitivity. The company’s recent cost‑cutting initiatives have produced sequential margin improvement, yet cash flow remains negative with operating cash flow of –$6.1 million. The recent reverse split may temporarily lift the share price but does not resolve underlying profitability issues. **Overall, the stock is priced cheaply relative to book and sales, but the fundamental deterioration and elevated risk profile limit upside potential.**
Given the weak earnings trajectory, high volatility, and liquidity constraints, the stock is best approached with caution. Valuation leans toward being **undervalued** on a relative basis, yet the lack of sustainable earnings and cash generation points to a **value‑oriented** investment thesis rather than growth. Investors should monitor execution of cost reductions and any improvement in cash flow before considering a position, while being prepared for significant price swings driven by market sentiment and the upcoming post‑split trading dynamics.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Pending 1‑for‑10 reverse split may cause price volatility
  • Decreasing volume and high 30‑day volatility
  • Neutral technical trend with modest bullish MACD

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Cost‑cutting initiatives showing early margin improvement
  • Persistent negative cash flow and earnings
  • Valuation remains cheap relative to book and sales

Long Term

> 3 years
Cautious
Model confidence: 3/10

Key Factors

  • Continued revenue decline and negative profitability
  • High debt‑to‑equity and weak ROE
  • Elevated beta and volatility indicating market sensitivity

Key Metrics & Analysis

Financial Health

Revenue Growth-21.10%
Profit Margin-19.26%
ROE-46.69%
ROA-16.95%
Debt/Equity9.03
P/B Ratio0.9
Op. Cash Flow$-6130000
Free Cash Flow$-1132750
Industry P/E36.9

Technical Analysis

TrendNeutral
RSI57.0
Support$3.40
Resistance$6.30
MA 20$5.07
MA 50$5.06
MA 200$6.68
MACDBullish
VolumeDecreasing
Fear & Greed Index86.36

Valuation

GradeUndervalued
TypeValue

Risk Assessment

Beta1.41
Volatility135.37%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.